Skip to main content

Cancer Care

Cancer Care

Sarah Cannon at Belton Regional Medical Center is proud to be part of the Sarah Cannon HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.

Sarah Cannon at Belton Regional Medical Center offers a comprehensive array of diagnostic services such as minimally-invasive technology for diagnosing and treating breast lesions, as well as a range of cancer care services from screenings, cancer treatment and survivorship. The site is staffed by skilled oncology nurses who provide a wide variety of oncology and infusion services.

Sarah Cannon at Belton Regional Medical Center builds on the current cancer program with genetic counseling services, nurse navigation programs, access to national clinical research trials and personalized medicine/tumor profiling.

Screenings and Self Assessments

Breast Cancer Colon Cancer

Visit to take more cancer risk assessments or to schedule a cancer screening. Call (816) 348-1900 for more information.

The Belton Regional Medical Center cancer program is accredited by the American College of Surgeons, Commission on Cancer (CoC). The CoC publishes the Cancer Programs Practice Profile Reports (CP³R) which includes two measures for colon cancer

The (CP³R) measurement helps facilities to:

  • Ensure patients are treated according to recognized standards of care,
  • Promote quality improvement activities, and
  • Accurately compare clinical performance among CoC accredited cancer programs.

The most current results for the two colon cancer measures include:

Quality Measure Belton Regional Medical Center Missouri National
Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer 100% 94% 91.6%
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer 100% 90.4% 87.8%